• Korro Bio Inc KRRO.OQ reported a quarterly adjusted loss of $1.65​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.26. The mean expectation of ten analysts for the quarter was for a loss of $2.07 per share. Wall Street expected results to range from $-3.19 to $-1.44 per share.

• Revenue fell 43.1% to $1.29 million from a year ago; analysts expected $540.00 thousand.

• Korro Bio Inc's reported EPS for the quarter was a loss of $5.33​.

• The company reported a quarterly loss of $50.04 million.

• Korro Bio Inc shares had risen by 59.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Korro Bio Inc is $20.00, about 36% above its last closing price of $12.80

This summary was machine generated from LSEG data March 16 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)